ARS Pharms Stock Price, News & Analysis

ARS Pharma (Nasdaq: SPRY) launched Get neffy on Us on November 4, 2025, an integrated commercial program to expand access to neffy (epinephrine nasal spray).

Key features: a free virtual prescriber visit taking 5–10 minutes, potential $0 co-pay for eligible commercially insured patients, and delivery to a pharmacy or home within 3–5 days. The company cites ~40 million people with severe allergies and survey interest of >70% in virtual prescribing. The program complements neffyInSchools, which has provided neffy to >6,600 schools across >20 states. More information is available at www.getneffy.com or 1-877-MY-NEFFY.

ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations featuring real-world data on neffy® (epinephrine nasal spray) at the 2025 ACAAI Annual Scientific Meeting in Orlando, Nov 6–10, 2025.

The late-breaking oral presentation, “Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update,” is scheduled for Nov 8, 2025 at 5:23 PM ET. Six poster sessions and five clinician case reports will report real-world use, safety, and administration topics. ARS will host onsite activities and exhibit at booth #400.

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.

Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.

ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations on neffy® (epinephrine nasal spray) at the ACAAI Annual Scientific Meeting, Nov 6-10, 2025 in Orlando.

Presentations include a late-breaking oral update reporting that about 9 of 10 patients with anaphylaxis were effectively treated with a single dose of neffy, five case reports of in-clinic use, and posters on patient experience, dosing technique, safety, stability, and second-dose rationale.

Attendees can visit booth #400 and multiple onsite sessions for more details.

ARS Pharmaceuticals (NASDAQ: SPRY) announced the European Patent Office Opposition Division upheld all claims of EP 3678649, a patent covering nasal spray epinephrine formulations including alkyl-glycoside excipients such as Intravail®. The patent is validated in over 30 European countries and ARS states its global intellectual property for neffy provides coverage through at least 2039. Earlier in 2025 the USPTO also upheld key claims of U.S. Patent No. 10,682,414 after an IPR challenge and appeal, giving ARS two different patents with differing claim scope sustained in separate jurisdictions.

Company commentary framed the rulings as reinforcing the strength of its worldwide patent estate that covers intranasal epinephrine.

ARS Pharmaceuticals (NASDAQ: SPRY) has secured a substantial $250 million senior secured term loan facility from RA Capital Management and OMERS Life Sciences. The company has initially borrowed $100 million to accelerate the commercialization of neffy®, their needle-free epinephrine treatment for allergic reactions.

The loan facility includes favorable terms with an interest rate of SOFR plus 5.5% and interest-only payments until September 2030. The company has access to additional tranches: $25 million available within 6-12 months, another $25 million subject to achieving $100 million in U.S. revenue, and an uncommitted $100 million incremental term loan.

Market response to neffy® has been strong, with 93% of patients surveyed being "very likely to consider" the treatment and the prescriber base nearly doubling in four months. The company expects the funding to support operations through cash-flow breakeven while targeting the $2 billion annual U.S. epinephrine market.

ARS Pharmaceuticals (NASDAQ:SPRY) has received Japanese regulatory approval for neffy®, the first needle-free epinephrine nasal spray for emergency treatment of allergic reactions (anaphylaxis). The approval covers both 1mg and 2mg doses for adults and children weighing over 15kg.

Through a partnership with Alfresa Holdings, neffy is expected to launch in Japan by Q4 2025. The approval triggers a $2 million milestone payment to ARS Pharma. This breakthrough addresses a significant market need, as approximately 900,000 Japanese individuals are affected by food allergies, yet only 14% of anaphylaxis patients reported having an epinephrine auto-injector prescription.

The product features a 24-month shelf life and is already commercially available in the US and parts of Europe, with additional approvals expected in Canada, Australia, New Zealand, and China by early 2026.

ARS Pharmaceuticals (NASDAQ:SPRY) has reported compelling real-world evidence for its neffy® (epinephrine nasal spray) in treating anaphylaxis. The study, accepted for publication in the Annals of Allergy, Asthma and Immunology, demonstrated that 89.2% of 545 patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy were successfully treated with a single dose of neffy.

This success rate closely mirrors the 88.9% efficacy rate historically reported for traditional epinephrine injections, suggesting clinical interchangeability between the two delivery methods. The findings build upon previous clinical evidence, including a Phase 3 study, and represent the first large-scale analysis of neffy's treatment outcomes in routine clinical practice.

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company focused on anaphylaxis prevention, announced its participation in two upcoming investor conferences. The company's leadership will present at the Cantor Global Healthcare Conference on September 3, 2025, at 3:55 p.m. ET in New York, and the Stifel Immunology and Inflammation Summit on September 15, 2025, at 12:00 p.m. ET virtually.

Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will represent the company. Live webcasts will be available on the company's website, with replays accessible for 30 days after each event.